New £4.3m Challenge Study Contract Win with Global Top 10 Vaccine Company
(WorldNews Health)

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new £4.3 million contract to conduct a human viral challenge study utilising one of our 8 traditional challenge study models for another of the global top 10 vaccine companies. This trial will be conducted in the Company`s dedicated human viral challenge quarantine unit in London with all volunteers recruited through hVIVO`s...